The objective of this study was to clarify the utility of nivolumab, irinotecan, and FTD/TPI monotherapy as third- or later-line treatment in Japanese patients with HER2-positive G/GEJ cancer who have previously received trastuzumab treatment. This evidence concerns the gene ERBB2 and cancer.